Express News | Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma
BenzingaApr 26 08:35 ET
Allogene Therapeutics Announces Q2 Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)
GlobeNewswireApr 9 08:30 ET
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Yahoo FinanceApr 7 10:22 ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
TipRanksMar 19 08:11 ET
Express News | HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target
Moomoo 24/7Mar 19 06:55 ET
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 16 16:35 ET
Allogene Therapeutics' Stability Threatened by Banking Sector Turmoil
TipRanksMar 16 02:01 ET
Express News | RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target
Moomoo 24/7Mar 15 12:19 ET
Allogene Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 115.29% RBC Capital → $10 Reiterates Outperform → Outperform 02/27/2024 72.23% JP Morgan $9 → $
BenzingaMar 15 12:17 ET
Allogene Therapeutics Files $500 Million Mixed Shelf
Allogene Therapeutics (ALLO) filed a registration statement Thursday for the potential sale of up to $500 million of securities from time to time. The filing covers the sale of the company's common st
MT NewswiresMar 15 03:27 ET
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
TipRanksMar 15 00:40 ET
Earnings Call Summary | Allogene Therapeutics(ALLO.US) Q4 2023 Earnings Conference
The following is a summary of the Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript:Financial Performance:Allogene Therapeutics ended Q4 2023 with a solid cash balance of $448.7 mill
moomoo AIMar 14 21:04 ET · Conference Call
Allogene Therapeutics Files for $500M Mixed Shelf
Seeking AlphaMar 14 17:37 ET
Recap: Allogene Therapeutics Q4 Earnings
Allogene Therapeutics (NASDAQ:ALLO) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:02 PM.Here's what investors need to know about the announcement.EarningsAllogene Therapeutics mis
BenzingaMar 14 16:20 ET
Allogene Therapeutics Q4 2023 GAAP EPS $(0.51) Misses $(0.46) Estimate, Sales $21.000K Miss $23.571K Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.46) by 10.87 percent. This is a 23.88 percent increase over losses
BenzingaMar 14 16:17 ET
Allogene Therapeutics: Co Expects a Decrease in Cash, Cash Equivalents, and Investments of Approximately $190M in 2024 >ALLO
Allogene Therapeutics: Co Expects a Decrease in Cash, Cash Equivalents, and Investments of Approximately $190M in 2024 >ALLO
Dow JonesMar 14 16:16 ET
Allogene Therapeutics: Based on Current Assumptions, the Co Continues to Expect Its Cash Runway to Fund Ops Into 2026 >ALLO
Allogene Therapeutics: Based on Current Assumptions, the Co Continues to Expect Its Cash Runway to Fund Ops Into 2026 >ALLO
Dow JonesMar 14 16:16 ET
Press Release: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update -- Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma
Dow JonesMar 14 16:05 ET
Allogene Therapeutics 4Q Loss $85.8M >ALLO
Allogene Therapeutics 4Q Loss $85.8M >ALLO
Dow JonesMar 14 16:05 ET
Notable Earnings After Thursday's Close
Seeking AlphaMar 13 17:35 ET
No Data
No Data